FRISBIE MEMORIAL HOSPITAL
1. Target Overview & Investment Thesis
FRISBIE MEMORIAL HOSPITAL is a 58-bed under-performing / distressed in nan, NH with $71.7M in net patient revenue and a -27.5% operating margin. The hospital serves a payer mix of 38.1% Medicare, 1.9% Medicaid, and 60.1% commercial.
Thesis: Turnaround. Our ML models identify $5.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -27.5% to -20.1% (+736bps).
| Net Revenue HCRIS | $71.7M |
| Current EBITDA COMPUTED | $-19.7M |
| Operating Margin COMPUTED | -27.5% |
| Occupancy HCRIS | 33.9% |
| Revenue / Bed COMPUTED | $1.2M |
| Net-to-Gross HCRIS | 19.3% |
| Distress Probability ML | 50.4% |
2. Market Context & Competitive Position
NH has 30 Medicare-certified hospitals with a median operating margin of -2.7%. The target's margin of -27.5% places it below the state median. Among 2099 size-comparable peers (29-116 beds), the median margin is -3.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (29-116), prioritizing same-state peers. 2099 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| FRISBIE MEMORIAL HOSPITAL (Target) | NH | 58 | $71.7M | -27.5% |
| DANA-FARBER CANCER INSTITUTE | MA | 30 | $1.88B | -35.1% |
| MIDWESTERN REGIONAL MEDICAL CE | IL | 73 | $1.38B | 80.5% |
| RANCHO LOS AMIGOS NATL.REHAB.C | CA | 83 | $512.6M | 41.9% |
| USC NORRIS CANCER HOSPITAL | CA | 60 | $468.7M | 19.1% |
| THE HEART HOSPITAL BAYLOR PLAN | TX | 109 | $464.6M | 25.7% |
| SARAH BUSH LINCOLN HEALTH CENT | IL | 100 | $448.6M | -18.1% |
| ST. JOSEPHS COMM. HOSPT. | WI | 70 | $436.8M | 66.1% |
| MCHS FRANCISCAN HEALTHCARE IN | WI | 103 | $413.8M | -7.2% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.3M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.5M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $1.4M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $1.4M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $872K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $46K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-19.7M |
| + RCM Uplift | +$5.3M |
| Pro Forma EBITDA | $-14.4M |
| Current Margin | -27.5% |
| Pro Forma Margin | -20.1% |
| WC Released (1x) | $2.7M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-30.3M | $-77.2M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-30.3M | $-94.7M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-27.3M | $-87.2M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-27.3M | $-103.2M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-33.3M | $-93.7M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-33.3M | $-113.9M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Low occupancy | At 33.9%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 50.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 2099 hospitals with 29-116 beds
- Same-state prioritization (n=7)
- Comp margins: P25=-16.3% / P50=-3.1% / P75=9.0%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.